# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# Zhang 2019 (Continued)

# • Endoscopic score

Notes: Blinding information of the study not available.

Abstract available in English. The study itself could not be translated.

5-ASA: 5-aminosalicylic acid; BMI: body mass index; CD: Crohn disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FMT: fecal microbiota transplantation; HTLV: human T-lymphotropic virus type; IBD: inflammatory bowel disease; n: number; PCDAI: Pediatric Crohn's Disease Activity Index; RCT: randomized controlled trial; UC: ulcerative colitis.

# Characteristics of ongoing studies [ordered by study ID]

|Study ID|Study name|Methods|Participants|Interventions|Outcomes|Starting date|
|---|---|---|---|---|---|---|
|CTRI/2021/03/032131|Stool transplant for treatment of colitis and Crohn's disease|RCT conducted in India|Inclusion criteria: - People with IBD ages ≥ 18 years at the time of enrollment with written informed consent to participate
Exclusion criteria: - Age < 18 years
- Pregnancy
- HIV-positive
- Disseminated or advanced malignancy
- Concomitant severe underlying systemic illness that, in the opinion of the investigator, would interfere with completion of follow-up
- Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
- Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of study
- Inability to provide informed consent
|Experimental arm: - FMT via colonoscopy
Control arm: - Sham colonoscopy
|Primary outcome: - Efficacy of FMT in UC and CD at weeks 4, 12, 24, and 52
Secondary outcomes: - Efficacy and safety of FMT in pouchitis and extra-intestinal manifestations of IBD at weeks 4, 12, 24, 52
- Microbiota profile of the donors and FMT recipients pre- and post-FMT, compared with donor microbiota profile, at weeks 4, 12, 24, and 52
- Safety of FMT in UC and CD at weeks 4, 12, 24, and 52
|1 April 2021|

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.